12:00 AM
 | 
Nov 01, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tezosentan (Ro 61-0612): Began Phase III trial

Actelion Ltd., Allschwil, Switzerland
Product: Tezosentan (Ro 61-0612)
Business: Cardiovascular
Therapeutic category: Receptor antagonist
Target: Endothelin receptors...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >